OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Axxam SpA

4 Projects | 2 Researchers | $1,210,000 Invested

2017

Axxam SpA

Paolo Pevarello, PhD

Exploratory Optimization of New CX3CR1 modulators for the treatment of AD.

  • Funding Amount: $300,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2014

Axxam SpA

Paolo Pevarello, PhD

In vivo assessment and optimization of P2X7 antagonists for AD treatment

  • Funding Amount: $350,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2013

Axxam SpA

Paolo Pevarello, PhD

Optimization of P2X7 antagonists for AD treatment

  • Funding Amount: $310,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Target: Neuroinflammation
  • Status: Closed

2011

Axxam SpA

Michela Stucchi, PhD

Small Molecule P2X7 Antagonists for AD Treatment

  • Funding Amount: $250,000
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed